Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

From the Department of Physiology and Cardiovascular Institute (Y.L., G.A.M., D.M.B.), Loyola University Chicago, Stritch School of Medicine, Maywood, Ill; Department ...

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab ...

There are conflicting data regarding the effects of TK inhibitors on tumor immunity (Table 2). Some reports demonstrated the immunostimulatory effects of a TK inhibitor, but others reported the ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...